Topic: combination therapy
Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.
Amgen’s Kyprolis is finally on track for blockbuster status this year, and new data in tandem with J&J's Darzalex could help boost it even further.
A manufacturing defect led to a 'softening' in response rates with a combo of its NKTR-214 and Opdivo in clinical trials, Nektar said.
The nod comes as Celgene and Roche are looking to add new indications to their old cancer stalwarts.
Array's combo for BRAF-positive colon cancer could be a blockbuster, analysts say—but only if it can prove safety and durability.
Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two.